SCHEMBL23717192

SCHEMBL23717192

CCC(C)N1CC(c2ccncc2)OC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.36
FADS1 O60427 4/20 0.34
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TMEM97 Q5BJF2 1/20 0.32
LDHA P00338 1/20 0.32
RIPK3 Q9Y572 1/20 0.32
TSHR P16473 1/20 0.32
CETP P11597 2/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CACNA1B Q00975 1/20 0.31
HTR7 P34969 1/20 0.31
TP53 P04637 1/20 0.30
DDB1 Q16531 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20780472 0.85 HTR2B (0.37) GRM2FADS1CDK4CCND1LMNA
SCHEMBL23717436 0.84 CYP2A6 (0.44) GRM2TSHRKDM4EMEN1KMT2A
SCHEMBL13413561 0.77 GRM2 (0.45) GRM2FADS1CDK4CCND1LMNA
SCHEMBL15743971 0.74 ALOX5 (0.41) GRM2FADS1CDK4CCND1LMNA
SCHEMBL9239754 0.72 TDP1 (0.43) GRM2FADS1CETPKDM4EMEN1
SCHEMBL13394528 0.72 HTR2B (0.37) GRM2FADS1CDK4CCND1LMNA
SCHEMBL13330256 0.71 TSHR (0.38) GRM2TSHR
SCHEMBL20794011 0.70 HTR2B (0.47) FADS1TSHRKDM4EKMT2ADDB1
SCHEMBL20780486 0.70 HTR2B (0.47) FADS1TSHRKDM4EKMT2ADDB1
SCHEMBL13837966 0.70 HTR2B (0.47) FADS1TSHRKDM4EKMT2ADDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210236442-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210236442-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES IAPP, SLC5A2, SLC2A2 GRM2 1142/4885FADS1 1182/4885CDK4 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.